Literature DB >> 4622104

Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.

A D Schreiber, M M Frank.   

Abstract

A model for the immune clearance and destruction of homologous erythrocytes has been further explored. In this model, every IgM anti-erythrocyte antibody molecule in an antibody preparation was shown to fix Cl. About 2000 IgG antibody molecules were required to form a Cl-fixing site on the guinea pig erythrocyte surface. 60 IgM complement-fixing sites per erythrocyte were required for the immune clearance of IgM-sensitized erythrocytes. This number of sites could be detected by a direct agglutination test. 1.4 complement-fixing sites were required for immune clearance of IgG-sensitized cells, a number of molecules which could not be detected by direct agglutination. This number could, however, be detected with the use of a Coombs antiglobulin reagent. Depletion of the late components of complement (C3-9) with cobra venom was associated with the loss of ability to clear IgM-sensitized cells and a marked deficit in the ability to clear IgG-coated cells. Thus, late (C3-9) components of complement as well as an early component (C4) were required for normal clearance of sensitized erythrocytes. There was no evidence that activation of the alternate pathway of complement action could lead to accelerated erythrocyte clearance. In vitro incubation of IgG and IgM-sensitized erythrocytes in fresh serum led to deposition of C3 and C4 on the erythrocyte surface. IgM-sensitized cells treated in this way had a normal survival. IgM-sensitized cells also were shown to remain Coombs positive after their release from the liver. The evidence suggests that the interaction of an IgM site with fresh serum in vitro and in vivo leads to formation of a site which allows for sequestration of cells in the liver. With continued exposure to serum components, this site is destroyed or inactivated. This serum-dependent inactivation is complement-dependent as shown by the use of EDTA-treated and C4-deficient serum. IgG complement-fixing sites are only partially inactivated by incubation in fresh serum, further emphasizing the differences in the biologic activity of IgM and IgG antibodies.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4622104      PMCID: PMC302164          DOI: 10.1172/JCI106847

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  The functional activities of IgG and IgM anti-A and anti-B.

Authors:  J Economidou; N C Hughes-Jones; B Gardner
Journal:  Immunology       Date:  1967-09       Impact factor: 7.397

2.  Haemolytic efficiency of rabbit IgG anti-Forssman antibody and its augmentation by anti-rabbit IgG.

Authors:  J H Humphrey
Journal:  Nature       Date:  1967-12-30       Impact factor: 49.962

3.  Chronic hemolytic anemia due to cold agglutinins: the mechanism of resistance of red cells to C' hemolysis by cold agglutinins.

Authors:  R S Evans; E Turner; M Bingham
Journal:  J Clin Invest       Date:  1967-09       Impact factor: 14.808

4.  Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G.

Authors:  H Huber; M J Polley; W D Linscott; H H Fudenberg; H J Müller-Eberhard
Journal:  Science       Date:  1968-12-13       Impact factor: 47.728

5.  Complement fixation on cell surfaces by 19S and 7S antibodies.

Authors:  T Borsos; H J Rapp
Journal:  Science       Date:  1965-10-22       Impact factor: 47.728

6.  Ca++-dependent binding of antigen-19 S antibody complexes to macrophages.

Authors:  W H Lay; V Nussenzweig
Journal:  J Immunol       Date:  1969-05       Impact factor: 5.422

7.  A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity.

Authors:  R A Nelson
Journal:  Surv Ophthalmol       Date:  1966-08       Impact factor: 6.048

8.  The detection of cell-bound antibody on complement-coated human red cells.

Authors:  B C Gilliland; J P Leddy; J H Vaughan
Journal:  J Clin Invest       Date:  1970-05       Impact factor: 14.808

9.  Chronic hemolytic anemia due to cold agglutinins. II. The role of C' in red cell destruction.

Authors:  R S Evans; E Turner; M Bingham; R Woods
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

10.  Receptors for complement of leukocytes.

Authors:  W H Lay; V Nussenzweig
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

View more
  39 in total

Review 1.  Use of mouse models to study the mechanisms and consequences of RBC clearance.

Authors:  E A Hod; S A Arinsburg; R O Francis; J E Hendrickson; J C Zimring; S L Spitalnik
Journal:  Vox Sang       Date:  2010-03-21       Impact factor: 2.144

2.  Pathogenesis of hemolysis in immune hemolytic anemia.

Authors:  J R Cohen
Journal:  West J Med       Date:  1977-10

3.  A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer.

Authors:  Michelle Elvington; Yuxiang Huang; B Paul Morgan; Fei Qiao; Nico van Rooijen; Carl Atkinson; Stephen Tomlinson
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

4.  A receptor for monomeric IgG2b on rat macrophages.

Authors:  S Denham; R Barfoot; E Jackson
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

5.  Effects of corticosteroids and splenectomy on the immune clearance and destruction of erythrocytes.

Authors:  J P Atkinson; A D Schreiber; M M Frank
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

6.  The complement fragment C3d facilitates phagocytosis by monocytes.

Authors:  T A Gaither; I Vargas; S Inada; M M Frank
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

7.  Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Authors:  Nisar A Baig; Ronald P Taylor; Margaret A Lindorfer; Amy K Church; Betsy R LaPlant; Adam M Pettinger; Tait D Shanafelt; Grzegorz S Nowakowski; Clive S Zent
Journal:  J Immunol       Date:  2014-01-15       Impact factor: 5.422

Review 8.  Phagocytosis. Clinical disorders of recognition and ingestion.

Authors:  T P Stossel
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

9.  A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia.

Authors:  E J Brown; S W Hosea; C H Hammer; C G Burch; M M Frank
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

10.  Increased efficiency of binding of nascent C3b to the erythrocytes of chronic cold agglutinin disease.

Authors:  C J Parker; C M Soldato; M J Telen
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.